RedHill Biopharma (RDHL) Income towards Parent Company (2012 - 2023)

RedHill Biopharma (RDHL) has reported Income towards Parent Company for 12 consecutive years, with $58.9 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Income towards Parent Company rose 791.8% year-over-year to $58.9 million in Q2 2023; TTM through Jun 2023 was -$40.0 million, a 64.44% increase from a year earlier, with the FY2025 full-year figure at -$429000.0, up 94.81% from the prior year.
• Income towards Parent Company was $58.9 million for Q2 2023 at RedHill Biopharma, up from -$7.9 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $58.9 million in Q2 2023 and troughed at -$145.2 million in Q4 2021.
• A 5-year average of -$1.3 million and a median of $11.1 million in 2019 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company plunged 1062.84% in 2021 and soared 791.8% in 2023, its largest moves.
• Over 5 years, Income towards Parent Company stood at $11.8 million in 2019, then gained by 27.44% to $15.1 million in 2020, then sank by 1062.84% to -$145.2 million in 2021, then surged by 52.14% to -$69.5 million in 2022, then jumped by 184.75% to $58.9 million in 2023.
• The last three Income towards Parent Company figures came in at $58.9 million (Q2 2023), -$7.9 million (Q1 2023), and -$69.5 million (Q4 2022), per Business Quant data.